A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Phase 1 Completed 23 enrolled Eli Lilly and Company

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.

Timeline

Start: 2016-10-21
Primary completion: 2018-11-05
Completion: 2019-01-22

Publications

Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S. Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist. 2020 Nov;25(11):e1628-e1639. doi: 10.1634/theoncologist.2020-0520. Epub 2020 Jul 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Merestinib	Small molecule	80 mg	Oral
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	Intravenous
Background	Abemaciclib	Small molecule	—	Oral

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Summary

Timeline

Publications

Drugs

Indications